Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-29Clinical Trial Update: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy [Phase 2]
Phase 2 trial comparing KTd vs KRd induction therapy in newly diagnosed multiple myeloma and investigating a K-mono maintenance strategy; st…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation [Phase 2, Phase 3]
A multi-phase clinical trial assessing low-dose CTX as maintenance therapy for newly diagnosed multiple myeloma patients unsuitable for tran…
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease [Phase 3]
Phase 3 trial comparing Narlumosbart with Denosumab in multiple myeloma bone disease is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM [Phase 1, Phase 2]
A combined belantamab mafodotin with aOX40 sub-study in relapsed/refractory multiple myeloma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) [Phase 1, Phase 2]
Clinical trial update for CT053 in relapsed/refractory multiple myeloma (LUMMICAR STUDY 1) spanning Phase 1 and Phase 2.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]
Phase 3 clinical trial evaluating monotherapy with BCD-264 and Darzalex in relapsed and refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma [Phase 2]
Phase II trial evaluating lenalidomide with subcutaneous bortezomib and dexamethasone for newly diagnosed multiple myeloma; results have bee…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Vaccine Therapy in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating a vaccine therapy in patients with stage II/III multiple myeloma; study completed.
-
FDA approval · 2024-03-01FDA Approved: NINLARO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for NINLARO (ixazomib) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2024-02-29Clinical Trial Update: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma [Phase 2, Phase 3]
Clinical trial update evaluating rivaroxaban versus aspirin for thromboprophylaxis in relapsed or progressive multiple myeloma (Phase 2/Phas…
-
FDA approval · 2024-02-20FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) filed by Janssen Biotech, Inc., marking an approval action relat…
-
FDA label_change · 2024-02-20FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TALVEY (talquetamab) from Janssen Biotech, Inc., resulting in updated labeling for the product.
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 trial assessing carfilzomib in combination with bendamustine and dexamethasone for refractory or relapsed multiple myeloma has c…
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer [Phase 2]
Phase 2 trial evaluating romiplostim to treat low platelets after chemotherapy and autologous hematopoietic cell transplantation in people w…
-
CLINICAL_TRIALS trial_result · 2024-02-13Clinical Trial Update: Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM [Phase 2]
Phase 2 clinical study evaluating reduced-dose pomalidomide and cyclophosphamide with dexamethasone for relapsed/refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-type dendritic cells as consolidation after autolog…
-
FDA approval · 2024-02-05FDA Approved: PLERIXAFOR — Supplemental Application (Meitheal Pharmaceuticals Inc.)
The FDA approved a supplemental application for Plerixafor by Meitheal Pharmaceuticals, granting approval for an additional submission relat…
-
CLINICAL_TRIALS trial_result · 2024-01-31Clinical Trial Update: Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement [Phase 2]
Phase 2 clinical trial investigating selinexor, pomalidomide, and dexamethasone for multiple myeloma with CNS involvement.
-
FDA approval · 2024-01-30FDA Approved: PLERIXAFOR — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved a supplemental application for plerixafor from Dr. Reddy's Laboratories, typically resulting in a labeling or usage modificatio…
-
FDA approval · 2024-01-30FDA Approved: PLERIXAFOR — Supplemental Application (Zydus Lifesciences Limited)
FDA approves a supplemental application for Plerixafor submitted by Zydus Lifesciences Limited.
-
CLINICAL_TRIALS trial_result · 2024-01-25Clinical Trial Update: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update on KQ-2003 CAR-T cell therapy for relapsed or refractory multiple myeloma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone [Phase 2]
Phase 2 trial evaluating subcutaneous Velcade combined with oral melphalan and prednisone or cyclophosphamide and prednisone or prednisone a…
-
CLINICAL_TRIALS trial_result · 2024-01-19Clinical Trial Update: Selinexor, Cyclophosphamide and Prednisone in Myeloma [Phase 2]
Phase 2 clinical trial evaluating selinexor in combination with cyclophosphamide and prednisone for relapsed or refractory multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
Phase 1 trial of AMG 420 in relapsed and/or refractory multiple myeloma was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma [Phase 4]
Phase 4 study evaluating safety, tolerability, and efficacy of Kyprolis (carfilzomib) in relapsed or refractory multiple myeloma has complet…